Mode
Text Size
Log in / Sign up

Microscopic Polyangiitis

Part of Vasculitis

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Microscopic Polyangiitis

4 trials tracked for Microscopic Polyangiitis: 3 in phase 3 or 4 and 1 with published results. The most-cited published study has 115 citations.

4Trials tracked
3Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 1 Phase 3 2 Other / NA 1
  1. Phase 3 Rituximab Vasculitis Maintenance Study Completed · 115 cited
  2. Phase 4 Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis Completed
  3. Phase 3 Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis Completed
  4. N/A An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis Completed

Showing the 4 most-cited and recently-updated of 4 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Vasculitis

Related studies from across the Vasculitis family.

Questions about Microscopic Polyangiitis

How does the mortality risk for microscopic polyangiitis compare to granulomatosis with polyangiitis?

Microscopic polyangiitis (MPA) generally carries a higher mortality risk than granulomatosis with polyangiitis (GPA), with studies showing poorer survival and higher hazard ratios for death in MPA patients.

Full answer →